{"name":"Peter J. Ruane, M.D., Inc.","slug":"peter-j-ruane-m-d-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Raltegravir and Atazanavir","genericName":"Raltegravir and Atazanavir","slug":"raltegravir-and-atazanavir","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"}]}],"pipeline":[{"name":"Raltegravir and Atazanavir","genericName":"Raltegravir and Atazanavir","slug":"raltegravir-and-atazanavir","phase":"marketed","mechanism":"This combination inhibits HIV replication by blocking integrase (raltegravir) and protease (atazanavir), preventing viral DNA integration and polyprotein processing.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}